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Abstract
Purpose of review—To review recent findings on immunity and vaccine development to
Chlamydia trachomatis.
Recent findings—There is increasing knowledge on the interactions between Chlamydia
trachomatis and infected host cells. During genital infection the organism avoids generating
protective immunity but immune responses to a number of chlamydial proteins have been
associated with reproductive tract pathology. Various vaccine and adjuvant preparations have been
tried experimentally. Information generated by proteomics and complex studies of serological and
T-lymphocyte immune responses points to novel vaccine candidates.
Summary—Chlamydia trachomatis, an obligate intracellular bacterium, is the commonest
sexually transmitted infection worldwide and is associated with reproductive pathology. To
develop rational vaccines it is necessary to understand the complex life-cycle of the organism, the
host immune response to infection and how these relate to disease. Infection does not prevent
reinfection and antibiotic treatment prevents antibody production at a population level. It remains
unclear what type of immune response would be sufficient to prevent infection and/or reinfection.
Although the prevalence and demographics of infection and the severity of disease associations
suggest it would be desirable, there is no vaccine currently available. A number of studies have
identified novel vaccine candidates.
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The clinical problem - Chlamydia trachomatis and reproductive tract
disease
Chlamydia trachomatis (Ct) is a gram-negative, obligate intracellular bacterium. Serovars A-
C cause trachoma, D-K cause the common sexually transmitted infection (STI), L1-L2 cause
lymphogranuloma venereum (LGV)[1]. This review focuses on immunity and vaccination
against the common STI.
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Prevalence of Ct STI in Europe is 1- 3% of the population between the ages of 18-44. Re-
infection is common and most cases are asymptomatic[2]. It is accepted that Ct STI in some
women leads to pelvic inflammatory disease (PID), tubal infertility and ectopic pregnancy
although the evidence remains associative. There is also pathology associated with genital
infection in men[3;4].
The host response to infection - Immunity and disease following Chlamydia
trachomatis STI
Since widespread antibiotic therapy was introduced serum anti-Ct antibodies have declined
in parallel with increased Ct prevalence[5**;6]. Whilst clearing infection, antibiotics may
alter the development of immunity. It remains controversial whether pathology is caused
directly by infection or by the immune response. There is evidence that women who make a
pro-inflammatory, interferon-γ (IFN-γ–) dominated cytokine response (T helper Type 1/
Th1 response) have less re-infection and infertility than those who make IL-10 and IL-4
dominated Th2 responses[7*;8*]. As IFN-γ induces a persistent non-infectious state in Ct in
vitro[9*;10] it remains unclear whether a Th1 response completely clears infection in vivo.
Th1 dependent IgG2 antibodies to Ct antigens are higher in women with cervicitis and
PID[11*] indicating that Th1 responses may be associated with inflammatory pathology.
The potential solution - Is a vaccine likely to be beneficial?
Modelling indicates that fully protective vaccination would eliminate Ct epidemics in 20
years. A partially effective vaccine would reduce disease in men and women, but cost-
benefit would be greater for vaccinating women only[12*]. To develop vaccines it is
necessary to understand how Ct gains entry to and survives inside host cells; which bacterial
proteins induce immune responses; and, which immune responses are protective.
Protective immunity generated by vaccination should not be confused with the immune
response to STI. This is due to the context in which Ct antigens are seen by the immune
system. In vaccination this is determined by the adjuvant(s) used and the route of
administration. In natural infection Ct has evolved mechanisms to ensure that immune
responses are suboptimal and/or are directed at proteins which are not essential for
transmission or reinfection.
Complexity in miniature – the Chlamydia trachomatis lifecycle
The Ct chromosome encodes nearly 1000 proteins. Most isolates have a plasmid encoding 8
or 9 proteins which influence bacterial gene transcription[13*]. Ct has a bi-morphic life-
cycle. The metabolically inactive, infectious, elementary bodies (EBs) have an extensively
cross-linked outer membrane which makes them very stable extracellularly. The main
structural components are the major outer membrane protein (MOMP/OmpA), OmcA and
OmcB. Other proteins are involved in tropism and attachment. Heinz et al [14*] used an in
silico approach and Liu et al[15*] used proteomics to identify several outer membrane
proteins which may be targets for intervention strategies.
Inside permissive cells, EBs transition into rapidly dividing reticulate bodies (RBs) within
host membrane bound inclusion bodies. Midway through the 48-72hr replication cycle some
RBs transition to infectious EBs. The inclusion body expands and EBs are released by cell
lysis or by extrusion of inclusion bodies. In vitro, persistent infection (blocking of RB to EB
transition and generation of aberrant RB forms) results from exposure to penicillin, IFN-γ,
HSV infection and nutrient deprivation[9*;10]. Skilton et al[16**] demonstrated that
penicillin removal from persistently infected cultures causes aberrant RBs to bud and form
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normal RBs which then complete replication. Whether persistent infection occurs in vivo
remains uncertain[9*;16**].
Manipulating the environment - Pathogen induced host cell changes
Ct can use the cystic fibrosis transmembrane conductance regulator (CFTR) membrane
protein to enter cells[17*]. CFTR upregulation is associated with Ct induced female
infertility[18*]. EB entry depends on host membrane protein disulfide isomerase (PDI)
[19*] which targets cross-linked EB outer membrane proteins. PDI is a component of the
estrogen receptor alpha (ERalpha) complex which associates with Ct attached to human
endometrial epithelial cells[20]. Interaction with the ERalpha complex may be a target for
prevention of infection as the co-receptor protein SRAP-1 is targeted by a Ct protease
(CT441) to inhibit ERalpha signalling[21*].
Inside host cells Ct circumvents endogenous stress mechanisms, prevents lysosomal fusion,
inhibits apoptosis, and evades intracellular innate immunity. Cocchiaro and Valdivia[22*]
reviewed intracellular survival mechanisms and Betts et al[23*] reviewed how Ct effector
proteins alter host cells. On entry, the EB protein TARP translocates into the cytoplasm, is
phosphorylated by Src and remodels actin to allow the EB to move within the cell. The EB
becomes surrounded by host cell membrane to form the inclusion body and Ct proteins are
inserted into the inclusion body membrane. The inclusion body diverts and fuses with host
cell vesicles containing nutrients necessary for replication. CPAF, a RB protease secreted
into the cytoplasm, degrades cytoskeletal elements to allow inclusion body expansion and
release of EBs; and processes intermediate-filament proteins to stabilize the inclusion bodies
and minimize exposure to intracellular innate immune mechanisms[24*]. CPAF also
degrades pro-apoptotic proteins[24*] and TARP interacts with the host adaptor protein
SHC1 to inhibit apoptosis[25*]. Caspase-1 activation promotes Ct replication[26*]. Ct
disrupts several signalling pathways[27*]. In epithelial cells RAS decouples from MAPK/
ERK (MEK) signalling although the effects differ in human and murine cells[28**]. The Ct
proteins ChlaDub1 and CT441 interfere with host cell NF-κB signalling[23*].
Fighting back - Immune responses to Chlamydia trachomatis
Each Ct protein may possess multiple antigenic epitopes that could be recognized by the
acquired immune system. Some Ct molecules (proteins, LPS, lipids and CpG-
oligonucleotides) have pathogen associated molecular patterns (PAMPS) which can be
recognized by innate immune system receptors (PRRs).
Avoiding innate immunity
Ct EBs have evolved to avoid innate immunity in the reproductive tract. Innate immune
mechanisms include those triggered by membrane bound host PRRs, such as the Toll-like
receptors (TLRs)[29] and NOD-1[30] which depend on NF-κB signalling. Although Ct LPS
and proteins activate PRRs in vitro, responses to live infection are more muted suggesting
that disruption of NF-κB signalling inhibits innate responses[31*]. NF-κB was degraded in
Ct infected human trophoblast cells [32*].
Fallopian tubes from Ct infected women with ectopic pregnancy have increased inducible
nitric oxide synthase/iNOS and increased pro-inflammatory molecules, activins, which are
involved in scarring[33*]. Thus inflammation may kill bacteria but chronic inflammation
can cause tissue damage and this may partly explain why this study, like others, failed to
detect Ct in diseased Fallopian tubes.
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Immunological markers of infection, pathology and protective immunity
Antibodies and T-lymphocyte responses to several Ct proteins have been described.
Infection rate and organism load on reinfection decrease with age suggesting development
of at least partial protective immunity[34].
Antibody responses require CD4-T-lymphocyte ‘help’. B-lymphocytes and antibodies
recognize ‘native-protein’ epitopes which are not necessarily linear, whereas T-lymphocytes
recognise short linear peptides in the context of self MHC-I for CD8-T-cells and self MHC-
II for CD4-T-cells. CD4-T-cells can be activated as pro-inflammatory Th17 and Th1 cells or
as Th2 cells. Both Th1 and Th2 cells help B-cells to make antibody but the immunoglobulin
subclasses produced differ. As different immunoglobulin subclasses vary in biological
activity this may be relevant to pathology following infection.
A major antigenic source is the inclusion body. Ct encodes 50 inclusion body (Inc) proteins,
22 of which are in inclusion membranes[35*]. Antibodies to Inc proteins are found in sera
from infected women[11*;35*], and both CD4-[36*] and CD8-[37*] T-cells respond to Inc
epitopes. Not all Ct proteins generate antibodies in every individual. Commercially available
tests detect anti-EB antibodies by immunofluorescence or anti-MOMP antibodies by ELISA.
Anti-EB antibodies were correlated with Fallopian tube damage in sub-fertile women[38].
ELISA assays suggest that Ct795[39*], and the plasmid encoded Pgp3[40*] may be good
serological markers of infection. Infected women have IgG antibodies to MOMP, IncB and
IncC and IgG2 (a Th1 dependent subclass) is the prevalent subclass of anti-Inc
antibodies[11*]. Antibody titres to IncB and IncC correlate with cervicitis and PID being
highest in cervicitis[11*]. CD4-T-cell responses to IncB and IncC in infertile women
generated a Th2 cytokine pattern whilst fertile women showed a Th1 pattern[8*].
Ct heat shock proteins (cHSPs) are analogous to human HSPs and antibodies to cHSP60 are
associated with autoimmunity[41*]. Ct STI is associated with antibodies to sperm in semen
and IgG antibodies to cHSP60 are associated with reproductive failure. Sperm have several
surface HSPs and cross-reaction with cHSPs may initiate autoimmune responses to
sperm[42*]. IgG responses to cHSP60 does not correlate with pathology in women[43*] but
women with tubal infertility have a high prevalence of antibodies to cHSP60[44*].
Rank and Whitum-Hudson[45*] reviewed experimental evidence for protective acquired
immunity. In guinea-pigs antibody protects against reinfection and serum IgG is more
important than local IgA. In mice both Th1 cells and antibody contribute directly to
protection. MOMP is immunodominant, but MOMP immunization only protects if the
protein is non-reduced, emphasizing the importance of native-protein B cell epitopes.
Antibiotic therapy clears experimental infection but prevents generation of immunity[45*].
Vaccination
Important considerations for vaccination include: who to vaccinate; which antigen(s) to use;
which administration route to use; and, which adjuvant to use.
There are two stages in the Ct lifecycle which a prophylactic vaccine should ‘hit’: 1) cell-
adhesion, for which antibody would be most useful and 2) early-mid replication where T-
cells might be targeted against bacterial antigens in infected cell membranes. Both responses
would require CD4-T-cell activation. Acquired immunity is polarized by the antigen
presenting cells (usually local dendritic cells/DCs) which first activate CD4-T-cell
responses. Thus adjuvant activation of DCs local to the vaccination site is crucial. It should
be remembered that although animal studies establish general principles, the fine details of
immunity differ between species, and, although Ct is closely related to the widely used
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murine pathogen C. muridarum (which is, somewhat confusingly, also referred to as the
mouse pneumonitis strain of C. trachomatis) their biology is not identical.
A strong IFN-γ response of lymphocytes to Ct antigen correlates with resistance to infection
among sex workers[46*]. An immunoproteomic analysis of C. muridarum indicates the two
most likely vaccine candidates were PmpG and PmpE/F which several mouse strains
recognise. However, peptides of these proteins used to vaccinate one mouse strain are not
recognized by others arguing for whole protein rather than peptide vaccination. CpG
oligonucleotide adjuvant does not induce protection perhaps due to lack of Th17
induction[46*]. The balance between Th1/Th17 responses explains different susceptibilities
of mouse strains to C. muridarum[47*]. MOMP administered in Lipid-C adjuvant both
transcutaneously[48*] and orally[49*] induces protection against vaginal C. muridarum
which is enhanced via the oral route when CpG oligonucleotides and cholera toxin are
incorporated into the Lipid-C[49*]. CT043, a conserved Inc protein, is a CD4-T-cell target
and may be a vaccine candidate[50*]. Ct ArtJ [a protein conserved among chlamydial
species] may also be a vaccine candidate with the additional benefit of also generating
protection against the related human lung pathogen C. pneumoniae[51**]. CPAF induces
protection against vaginal C. muridarum which is boosted with IL-12 or CpG
oligonucleotides as adjuvant[52*]. Live infection induces Th1 responses whilst
immunization with inactivated organisms induces Th2 responses[53*]. TARP is an
immunodominant protein and protects mice against C. muridarum infection[54*].
The human Ct “antigen-ome” in sera from 99 infected women is very broad as over 700 Ct
proteins were recognized by more than one serum[55**]. Mice given either live CT
infection or immunized with dead organisms were used to identify infection dependent and
independent antigens which were tested against sera from infected women. The most
recognized infection dependent protein (by 94% of sera) is CPAF. The most recognized
infection independent protein (by 96% of sera) is Pgp3[55**]. Use of serologically
recognized proteins to identify CD4-T-cell epitopes also identified CPAF as a widely
recognized serological antigen although in this series CT875 was the most commonly
recognized protein[56**]. MOMP is the most widely recognised T-cell epitope but CT875
stimulates most combined T-cell and serum responses[56**].
Concluding remarks
Understanding the natural history of infection, the host immune response and how these
impact on subsequent pathology is crucial to rational vaccine design. Prophylactic
vaccination aims to protect before infection. Therapeutic vaccination aims to boost or alter
the immune response generated in previously infected individuals. There can be no doubt
that vaccines against Ct would be of benefit to health and are likely to have a significant
impact on healthcare costs. More work on identifying and testing vaccine candidates and
appropriate delivery systems is needed.
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Abbreviations
CFTR cystic fibrosis transmembrane conductance regulator protein
ChlaDub1 Chlamydial Deubiquitinase and deneddylase Dub1
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CPAF chlamydial protease/proteasome-like activity factor
Ct Chlamydia trachomatis
DC dendritic cell
EB elementary body
ELISA enzyme linked immunosorbent assay
ERalpha estrogen receptor alpha
HSP heat shock protein
HSV herpes simplex virus
IFN-γ interferon-γ
IgG2 Immunoglobulin subclass G2
LGV lymphogranuloma venereum
IL interleukin
iNOS inducible nitric oxide synthase
LPS lipopolysaccharide
MAPK /ERK mitogen activated protein kinase
MHC Major Histocompatibility Complex (protein)
MOMP major outer membrane protein
NF-κB nuclear factor kappa-B
NOD-1 nucleotide-binding oligomerization domain containing 1
PAMP pathogen associated molecular pattern
PDI protein disulfide isomerase
PID pelvic inflammatory disease
PRR pattern recognition receptor
RAS RAt sarcoma GTPase
RB reticulate body
SRAP-1 Steroid receptor RNA activator 1
STI sexually transmitted infection
TARP translocated actin recruiting phosphoprotein
Th T helper lymphocyte
TLR Toll-like receptor
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Key Points
• Chlamydia trachomatis genital infection is associated with subsequent
reproductive pathology and infertility
• Infection with Chlamydia trachomatis induces partial immunity at best
• Vaccination against Chlamydia trachomatis would significantly reduce disease
burden and health care costs
• Protective immunity can be induced experimentally
• Human Chlamydia trachomatis vaccine candidates and adjuvants require further
study
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